Athanassiou P, Katsimbri P, Bounas A, Gazi S, Sarikoudis T, Syrigou V
Clin Rheumatol. 2024; 43(5):1469-1478.
PMID: 38472527
PMC: 11018651.
DOI: 10.1007/s10067-024-06916-5.
Alten R, An Y, Kim D, Yoon S, Peyrin-Biroulet L
Clin Drug Investig. 2022; 42(6):477-489.
PMID: 35657560
DOI: 10.1007/s40261-022-01162-6.
Carballo N, Garcia-Alzorriz E, Ferrandez O, Navarrete-Rouco M, Duran-Jorda X, Perez-Garcia C
Front Pharmacol. 2021; 12:752879.
PMID: 34912219
PMC: 8667555.
DOI: 10.3389/fphar.2021.752879.
Emery P, van Hoogstraten H, Thangavelu K, Mangan E, St John G, Verschueren P
ACR Open Rheumatol. 2020; 2(11):672-680.
PMID: 33164349
PMC: 7672306.
DOI: 10.1002/acr2.11188.
Roszkiewicz J, Swacha Z, Smolewska E
Pediatr Rheumatol Online J. 2020; 18(1):64.
PMID: 32787934
PMC: 7425569.
DOI: 10.1186/s12969-020-00455-4.
A Preclinical Investigation into the Effects of Aging on Dermal Hyaluronan Properties and Reconstitution Following Recombinant Human Hyaluronidase PH20 Administration.
Connor R, Blouw B, Cowell J, Chen K, Zhao C, Kang D
Dermatol Ther (Heidelb). 2020; 10(3):503-513.
PMID: 32361894
PMC: 7211778.
DOI: 10.1007/s13555-020-00380-0.
Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years old.
Gandell D, Bienen E, Gudeman J
Patient Prefer Adherence. 2019; 13:351-361.
PMID: 30863023
PMC: 6391128.
DOI: 10.2147/PPA.S187120.
Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
Matsui T, Umetsu R, Kato Y, Hane Y, Sasaoka S, Motooka Y
Int J Med Sci. 2017; 14(2):102-109.
PMID: 28260984
PMC: 5332837.
DOI: 10.7150/ijms.17025.
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.
Cha J, Park D, Park S, Shin J, Kim W, Yang S
J Korean Med Sci. 2016; 32(1):85-94.
PMID: 27914136
PMC: 5143303.
DOI: 10.3346/jkms.2017.32.1.85.
A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise Study.
De Mits S, Lenaerts J, Vander Cruyssen B, Mielants H, Westhovens R, Durez P
PLoS One. 2016; 11(11):e0166607.
PMID: 27893771
PMC: 5125609.
DOI: 10.1371/journal.pone.0166607.
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Harnett J, Gerber R, Gruben D, Koenig A, Chen C
J Manag Care Spec Pharm. 2016; 22(12):1457-1471.
PMID: 27882833
PMC: 10397820.
DOI: 10.18553/jmcp.2016.22.12.1457.
Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic.
Johnston S, McMorrow D, Farr A, Juneau P, Ogale S
Drugs Real World Outcomes. 2016; 2(1):99-109.
PMID: 27747619
PMC: 4883205.
DOI: 10.1007/s40801-015-0018-5.
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
Abdallah H, Hsu J, Lu P, Fettner S, Zhang X, Douglass W
J Clin Pharmacol. 2016; 57(4):459-468.
PMID: 27599663
PMC: 5363244.
DOI: 10.1002/jcph.826.
Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making.
Bolge S, Goren A, Brown D, Ginsberg S, Allen I
Patient Prefer Adherence. 2016; 10:1079-90.
PMID: 27390518
PMC: 4913989.
DOI: 10.2147/PPA.S107790.
Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain.
Nolla J, Rodriguez M, Martin-Mola E, Raya E, Ibero I, Nocea G
Patient Prefer Adherence. 2016; 10:1101-13.
PMID: 27382258
PMC: 4920238.
DOI: 10.2147/PPA.S106311.
Patients' Preference for a Specific Anti-Tumor Necrosis Factor Agent: Korea versus Western.
Seo H, Ye B
Gut Liver. 2016; 10(3):327-9.
PMID: 27114431
PMC: 4849682.
DOI: 10.5009/gnl16109.
Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study).
Kim E, Kim K, Jang B, Lee C, Kim H, Lee K
Gut Liver. 2015; 10(3):391-8.
PMID: 26347512
PMC: 4849692.
DOI: 10.5009/gnl15126.
Biologic agents for IBD: practical insights.
Danese S, Vuitton L, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2015; 12(9):537-45.
PMID: 26284562
DOI: 10.1038/nrgastro.2015.135.
An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.
Kerdel F, Zaiac M
Dermatol Ther. 2015; 28(6):390-403.
PMID: 26258910
PMC: 5042073.
DOI: 10.1111/dth.12267.
Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis.
Furst D, Shaikh S, Greenwald M, Bennett B, Davies O, Luijtens K
Arthritis Care Res (Hoboken). 2014; 67(2):151-60.
PMID: 25302624
PMC: 4329409.
DOI: 10.1002/acr.22496.
